HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $8.50 million. The enterprise value is $10.78 million.
| Market Cap | 8.50M |
| Enterprise Value | 10.78M |
Important Dates
The last earnings date was Thursday, July 23, 2026, after market close.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 3.90 million shares outstanding. The number of shares has increased by 179.82% in one year.
| Current Share Class | 3.90M |
| Shares Outstanding | 3.90M |
| Shares Change (YoY) | +179.82% |
| Shares Change (QoQ) | -0.65% |
| Owned by Insiders (%) | 19.61% |
| Owned by Institutions (%) | 5.53% |
| Float | 3.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,968.25 |
| Forward PS | 23.78 |
| PB Ratio | 30.87 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,496.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.53, with a Debt / Equity ratio of 17.41.
| Current Ratio | 0.53 |
| Quick Ratio | 0.34 |
| Debt / Equity | 17.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.17 |
Financial Efficiency
Return on equity (ROE) is -4,239.91% and return on invested capital (ROIC) is -143.02%.
| Return on Equity (ROE) | -4,239.91% |
| Return on Assets (ROA) | -110.86% |
| Return on Invested Capital (ROIC) | -143.02% |
| Return on Capital Employed (ROCE) | -2,095.04% |
| Weighted Average Cost of Capital (WACC) | 14.42% |
| Revenue Per Employee | $288 |
| Profits Per Employee | -$609,458 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.53% in the last 52 weeks. The beta is 1.79, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -34.53% |
| 50-Day Moving Average | 2.29 |
| 200-Day Moving Average | 2.59 |
| Relative Strength Index (RSI) | 42.44 |
| Average Volume (20 Days) | 45,223 |
Short Selling Information
The latest short interest is 77,601, so 1.99% of the outstanding shares have been sold short.
| Short Interest | 77,601 |
| Short Previous Month | 123,640 |
| Short % of Shares Out | 1.99% |
| Short % of Float | 2.48% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, HeartSciences had revenue of $4,319 and -$9.14 million in losses. Loss per share was -$3.48.
| Revenue | 4,319 |
| Gross Profit | 2,551 |
| Operating Income | -8.41M |
| Pretax Income | -9.14M |
| Net Income | -9.14M |
| EBITDA | -8.39M |
| EBIT | -8.41M |
| Loss Per Share | -$3.48 |
Balance Sheet
The company has $1.66 million in cash and $3.94 million in debt, with a net cash position of -$2.28 million or -$0.58 per share.
| Cash & Cash Equivalents | 1.66M |
| Total Debt | 3.94M |
| Net Cash | -2.28M |
| Net Cash Per Share | -$0.58 |
| Equity (Book Value) | 226,060 |
| Book Value Per Share | 0.07 |
| Working Capital | -2.28M |
Cash Flow
In the last 12 months, operating cash flow was -$7.43 million and capital expenditures -$3,554, giving a free cash flow of -$7.43 million.
| Operating Cash Flow | -7.43M |
| Capital Expenditures | -3,554 |
| Depreciation & Amortization | 27,791 |
| Net Borrowing | 2.31M |
| Free Cash Flow | -7.43M |
| FCF Per Share | -$1.91 |
Margins
| Gross Margin | 59.06% |
| Operating Margin | -194,787.38% |
| Pretax Margin | -211,666.47% |
| Profit Margin | n/a |
| EBITDA Margin | -194,143.92% |
| EBIT Margin | -194,787.38% |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -179.82% |
| Shareholder Yield | -179.82% |
| Earnings Yield | -107.54% |
| FCF Yield | -87.41% |
Analyst Forecast
The average price target for HeartSciences is $10.00, which is 358.72% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.00 |
| Price Target Difference | 358.72% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 3,680.42% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
HeartSciences has an Altman Z-Score of -27.55 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.55 |
| Piotroski F-Score | 2 |